Tropisetron enhances recognition memory in ovariectomized female rats.

The present study evaluated the acute effects of the 5-HT3 receptor antagonist, tropisetron, on recognition memory in ovariectomized adult female rats. The non-spatial novel object recognition task was used to assess recognition memory. In this task, ovariectomized rats explored two identical objects during Trial 1. Immediately after Trial 1, rats were primed either with oil, 250 µg progesterone, 20 µg of estrogen, or 20 µg of estrogen + 250 µg progesterone. Four hours later, the test trial (Trial 2) was initiated. Thirty minutes before Trial 2, rats were injected intraperitoneally with either saline, 1.5 or 2.5 mg/Kg tropisetron. During Trial 2, one arm of the T maze contained an object from Trial 1 (familiar or previously encountered), and a new object (novel) was introduced into the other arm. Exploration times with the novel and familiar objects were recorded and data were converted to percent time spent with the novel object. In oil-primed ovariectomized female rats, treatment with 2.5 mg/Kg tropisetron significantly increased percent time with the novel object. Hormonal-priming with estrogen, progesterone, or estrogen + progesterone did not further accentuate the effects of tropisetron. These results suggest that although tropisetron, estrogen, and progesterone all act as antagonists at the 5-HT3 receptors and blocking 5-HT3 receptors enhances cognition, there appears to be no interaction between tropisetron and these hormones on object recognition.

Tropisetron, a 5-HT(3) receptor antagonist, enhances object exploration in intact female rats.

The effects of a 5-HT(3) receptor antagonist, tropisetron, on cognitive functions were evaluated using the object-recognition test in estrous (postovulatory) and in diestrous female rats. Recognition was measured by the ability of rats to discriminate between a familiar and a new object in a T-maze after a 3-h delay. Rats from both stages spent equivalent amounts of time exploring the objects on trial 1. Three hours after trial 1, trial 2 (test trial) was initiated. Before the test trial, rats were injected with either saline or 1.5 or 2.5 mg/kg tropisetron. During the test trial, one arm of a T-maze contained an object from trial 1 (familiar) and a new object (novel) was introduced into the other arm. Rats from both stages responded to tropisetron by showing a greater percentage of time exploring the novel object. These findings indicate that tropisetron facilitates cognition in female rats by improving the recognition of familiar information.

Tropisetron increases the inhibitory effect of mild restraint on lordosis behavior of hormonally primed, ovariectomized rats.

Ovariectomized rats, hormonally primed with 10 µg estradiol benzoate and 500 µg progesterone are resistant to the lordosis-inhibiting effects of a 5 min restraint experience. However, modulation of the serotonergic (5-HT) system alters this resistance to stress. In the following experiment, ovariectomized Fischer inbred rats were hormonally primed with 10 µg estradiol benzoate and 500 µg progesterone. The effect of 5 min restraint on sexual behavior was examined after bilateral hypothalamic infusion or intraperitoneal (ip) treatment with the 5-HT(3) receptor antagonist, 3-tropanylindole-3-carboxylate hydrochloride (tropisetron). Infusion with 50 or 100 ng tropisetron inhibited lordosis behavior. When rats were infused with 10 or 25 ng tropisetron, rats showed normal lordosis behavior. However, when infusion with 10 or 25 ng tropisetron was combined with 5 min restraint, lordosis behavior was inhibited. These findings are consistent with prior work that has implicated hypothalamic serotonin in control of lordosis behavior and in the effect of mild restraint on the behavior. In contrast to the effects of the intracranial infusion, intraperitoneal injection with 1.0 or 2.0 mg/kg tropisetron did not amplify the effects of restraint.

Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test.

The effects of tropisetron, a 5-HT3 receptor antagonist, were evaluated in adult Fischer female rats exposed to the Forced Swim Test (FST). Rats selected on the days of proestrus or estrus was immersed in a cylinder of water for 2 consecutive days. Rats were exposed to the FST for 15 min on day 1 (pretest), followed by a 5-min session (test), 24 h later. The proestrous-estrous group consisted of rats that were exposed to the FST on their proestrous stage (pretest); then 24 h later the same rats were exposed to the FST on their estrous stage (test). Rats in the estrous-diestrous group were exposed to the FST on their estrous stage (pretest) and 24 h later on their diestrous stage (test). Rats were injected intraperitoneally with saline or 1.0 or 2.0 mg/kg tropisetron 30 min prior to exposure to the cylinder on the test day. Immobility, swimming, and struggling behaviors were scored for 5 min. There was a significant decline in immobility after treatment with 2.0 mg/kg tropisetron in both groups. In addition, a significant decline in swimming was observed in the estrous rats (proestrous-estrous group) after treatment with 2.0 mg/kg tropisetron. There were no significant effects of tropisetron on struggling in any groups examined.

Strain differences in the response to the 5-HT1A receptor agonist, 8-OH-DPAT.

Fischer and Sprague-Dawley ovariectomized rats were hormonally primed with estradiol benzoate (EB) and progesterone, and the ability of the 5-HT(1A) receptor agonist, (+/-) 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), to inhibit lordosis behavior was examined. Both strains showed rapid inhibition of lordosis behavior following either intraperitoneal or subcutaneous treatment with 8-OH-DPAT. Similarly, in both strains, pretreatment with EB (1 week prior to estrogen and progesterone priming) attenuated the lordosis-inhibiting effects of 8-OH-DPAT. However, Sprague-Dawley females showed a greater decline in lordosis behavior with a lower dose of 8-OH-DPAT than did Fischer females. The strain difference was present in females that had been preprimed with EB as well as in females receiving a single estrogen and progesterone priming. Moreover, strain differences were present across different priming doses of EB. Sprague-Dawley females were also more likely to show flat body posture after injection with 8-OH-DPAT so that the greater sensitivity of this strain to the 5-HT(1A) receptor agonist was not restricted to the drug's effect on lordosis behavior. These findings lead to the suggestion that, relative to Fischer rats, Sprague-Dawley females are more responsive to the 5-HT(1A) receptor agonist. Possible explanations for this strain difference are discussed.